Sigyn Therapeutics (SIGY) Total Current Liabilities (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Total Current Liabilities of $4.0 million for Q3 2025, down 27.32% sequentially from $5.5 million in Q2 2025, and down 6.68% YoY from $4.3 million in Q3 2024.
Sigyn Therapeutics (SIGY) Total Current Liabilities (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Total Current Liabilities for 10 years, with the latest figure at $4.0 million in Q3 2025.
- Quarterly Total Current Liabilities fell 6.68% year-over-year to $4.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.0 million (down 6.68% YoY) and the FY2024 annual result came in at $4.6 million, up 27.91% from the prior year.
- Total Current Liabilities slipped to $4.0 million in Q3 2025 per SIGY's latest filing, from $5.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.5 million in Q2 2025 and troughed at $689213.0 in Q1 2021.
- A 5-year average of $2.9 million and a median of $3.2 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2021 and 2023: Total Current Liabilities sank 78.48% in 2021, then surged 197.99% in 2023.
- Over 5 years, Total Current Liabilities stood at $734218.0 in 2021, then jumped by 179.03% to $2.0 million in 2022, then jumped by 76.11% to $3.6 million in 2023, then grew by 27.91% to $4.6 million in 2024, then decreased by 13.55% to $4.0 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $4.0 million, $5.5 million, and $5.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 5.15 Mn |
| Dec 31, 2024 | 4.61 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 4.23 Mn |
| Dec 31, 2023 | 3.61 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.83 Mn |
| Dec 31, 2022 | 2.05 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 1.36 Mn |
| Mar 31, 2022 | 950,848.00 |
| Dec 31, 2021 | 734,218.00 |
| Sep 30, 2021 | 829,784.00 |
| Jun 30, 2021 | 753,640.00 |
| Mar 31, 2021 | 689,213.00 |
| Dec 31, 2020 | 594,903.00 |